Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01019850 · ClinicalTrials.gov registry record · Phase 1
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
A Phase 1 study, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01019850 is a Phase 1 study that has completed, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 27 participants.
The verdict
NCT01019850, a Phase 1 study, has completed, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as iobenguane I 131, may carry radiation directly to tumor cells and not harm normal cells. Giving vorinostat together with iobenguane I 131 may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving vorinostat together with iobenguane I 131 in treating patients with resistant or relapsed neuroblastoma.
Interventions
- DRUG Vorinostat
- DRUG Filgrastim
- RADIATION 131- I Metaiodobenzylguanidine
- PROCEDURE Peripheral Blood Stem Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01019850
The ClinicalTrials.gov registry entry for NCT01019850 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Approaches to Neuroblastoma Therapy Consortium, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vorinostat is the first listed.
NCT01019850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01019850 about?
NCT01019850 is a clinical study titled "N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma". RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as iobenguane I 131, may carry radiation directly to tumor cells and not harm normal cells. Giving vorinostat together with iobenguane I 131 may kill more tumor ce...
What is the current status of trial NCT01019850?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-03. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01019850?
The interventions under investigation include: Vorinostat (DRUG), Filgrastim (DRUG), 131- I Metaiodobenzylguanidine (RADIATION), Peripheral Blood Stem Cell Infusion (PROCEDURE).
Who is sponsoring clinical trial NCT01019850?
This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.